Pavan Reddy

List of Publications by Year
in descending order

156	12,271	26630	26613
papers	citations	56 h-index	107 g-index

161	161	161	11454
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Graft-versus-host disease. Lancet, The, 2009, 373, 1550-1561.	13.7	2,093
2	Gut microbiomeâ€“derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nature Immunology, 2016, 17, 505-513.	14.5	536
3	Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine, 2002, 8, 575-581.	30.7	495
4	Pathophysiology of Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 3-10.	3.4	358
5	A biomarker panel for acute graft-versus-host disease. Blood, 2009, 113, 273-278.	1.4	348
6	ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. New England Journal of Medicine, 2013, 369, 529-539.	27.0	339
7	Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3921-3926.	7.1	278
8	Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood, 2011, 118, 6702-6708.	1.4	277
9	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenaseâ€“dependent DC functions and regulates experimental graft-versus-host disease in mice. Journal of Clinical Investigation, 2008, 118, 2562-73.	8.2	243
10	Immunobiology of acute graft-versus-host disease. Blood Reviews, 2003, 17, 187-194.	5.7	234
11	Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease. Journal of Immunology, 2004, 172, 7393-7398.	0.8	225
12	A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nature Medicine, 2005, 11, 1244-1249.	30.7	223
13	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
14	Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biology of Blood and Marrow Transplantation, 2003, 9, 505-511.	2.0	204
15	Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood, 2008, 112, 1515-1521.	1.4	198
16	Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood, 2008, 111, 2470-2475.	1.4	183
17	Current and emerging strategies for the prevention of graft-versus-host disease. Nature Reviews Clinical Oncology, 2014, 11, 536-547.	27.6	180
18	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight, 2017, 2, e89798.	5.0	166

#	Article	IF	Citations
19	Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis. Journal of Experimental Medicine, 2001, 194, 1433-1440.	8.5	161
20	Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. Clinical Cancer Research, 2011, 17, 77-88.	7.0	155
21	Manipulating the Bioenergetics of Alloreactive T Cells Causes Their Selective Apoptosis and Arrests Graft-Versus-Host Disease. Science Translational Medicine, 2011, 3, 67ra8.	12.4	153
22	Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology, 2003, 31, 897-902.	0.4	152
23	Pathophysiology of acute graft-versus-host disease. Hematological Oncology, 2003, 21, 149-161.	1.7	145
24	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood, 2018, 131, 2846-2855.	1.4	140
25	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood, 2011, 117, 6172-6183.	1.4	132
26	Interleukin-18: recent advances. Current Opinion in Hematology, 2004, 11, 405-410.	2.5	129
27	Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-3. Journal of Immunology, 2009, 182, 5899-5903.	0.8	129
28	Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 564-569.	7.1	125
29	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncology, The, 2014, 15, 87-95.	10.7	113
30	Pathophysiology of acute graft-versus-host disease: recent advances. Translational Research, 2007, 150, 197-214.	5.0	110
31	Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nature Communications, 2018, 9, 3674.	12.8	102
32	Mouse Models of Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 129-135.	2.0	98
33	Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood, 2003, 102, 429-435.	1.4	97
34	Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood, 2015, 125, 815-819.	1.4	95
35	Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease. Blood, 2011, 118, 192-204.	1.4	94
36	Survival signal REG3Î± prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. Journal of Clinical Investigation, 2018, 128, 4970-4979.	8.2	94

#	Article	IF	Citations
37	Acute Graft-versus-Host Disease: Novel Biological Insights. Biology of Blood and Marrow Transplantation, 2016, 22, 11-16.	2.0	92
38	Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoieticâ€“derived antigen-presenting cells. Blood, 2012, 119, 3844-3853.	1.4	86
39	Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives. Frontiers in Immunology, 2016, 7, 539.	4.8	85
40	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2018, 24, 1322-1340.	2.0	85
41	Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 351-357.	2.4	84
42	Mature T cell responses are controlled by microRNA-142. Journal of Clinical Investigation, 2015, 125, 2825-2840.	8.2	81
43	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood, 2018, 131, 1372-1379.	1.4	81
44	Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes. Biology of Blood and Marrow Transplantation, 2014, 20, 1407-1417.	2.0	80
45	Siglec-Gâ€“CD24 axis controls the severity of graft-versus-host disease in mice. Blood, 2014, 123, 3512-3523.	1.4	76
46	Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 1249-1256.	8.2	76
47	Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood, 2003, 102, 763-771.	1.4	74
48	Lung parenchyma-derived IL-6 promotes IL-17Aâ€“dependent acute lung injury after allogeneic stem cell transplantation. Blood, 2015, 125, 2435-2444.	1.4	73
49	Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8Î±+ dendritic cells and reduces experimental acute graft-versus-host disease. Blood, 2002, 99, 1825-1832.	1.4	72
50	Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. Journal of Clinical Investigation, 2017, 127, 1574-1588.	8.2	72
51	GVHD pathophysiology: is acute different from chronic?. Best Practice and Research in Clinical Haematology, 2008, 21, 101-117.	1.7	71
52	HDAC Inhibition and Graft Versus Host Disease. Molecular Medicine, 2011, 17, 404-416.	4.4	71
53	Critical role of host Î³Î´ T cells in experimental acute graft-versus-host disease. Blood, 2005, 106, 749-755.	1.4	67
54	Advances in understanding the pathogenesis of graftâ€versusâ€host disease. British Journal of Haematology, 2016, 173, 190-205.	2.5	67

#	Article	IF	Citations
55	Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood, 2013, 122, 2062-2073.	1.4	66
56	Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood, 2003, 101, 2877-2885.	1.4	65
57	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Advances, 2019, 3, 4034-4042.	5.2	63
58	Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood, 2017, 130, 1760-1767.	1.4	57
59	Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Experimental Hematology, 2008, 36, 988-996.	0.4	56
60	Tissue tolerance: a distinct concept to control acute GVHD severity. Blood, 2017, 129, 1747-1752.	1.4	56
61	The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. Blood, 2013, 122, 4119-4128.	1.4	54
62	A Crucial Role for Host APCs in the Induction of Donor CD4+CD25+ Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease. Journal of Immunology, 2010, 185, 3866-3872.	0.8	47
63	Biology of Graft-versus-Host Responses: Recent Insights. Biology of Blood and Marrow Transplantation, 2013, 19, S10-S14.	2.0	47
64	A Critical Analysis of the Role of SNARE Protein SEC22B in Antigen Cross-Presentation. Cell Reports, 2017, 19, 2645-2656.	6.4	42
65	BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood, 2015, 125, 2724-2728.	1.4	41
66	miR-142 controls metabolic reprogramming that regulates dendritic cell activation. Journal of Clinical Investigation, 2019, 129, 2029-2042.	8.2	41
67	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 862-868.	2.0	40
68	FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplantation, 2016, 51, 511-520.	2.4	40
69	Microbial metabolites and graft versus host disease. American Journal of Transplantation, 2018, 18, 23-29.	4.7	40
70	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 2019, 51, 479-490.e6.	14.3	39
71	Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood, 2002, 100, 3429-3431.	1.4	37
72	Role of interleukin-18 in acute graft-vs-host disease. Translational Research, 2003, 141, 365-371.	2.3	37

#	Article	IF	Citations
73	Role of Cytokines in the Pathophysiology of Acute Graft-Versus-Host Disease (GVHD)â€“ Are Serum/Plasma Cytokines Potential Biomarkers for Diagnosis of Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)?. Current Stem Cell Research and Therapy, 2012, 7, 229-239.	1.3	37
74	Siglec-G represses DAMP-mediated effects on T cells. JCI Insight, 2017, 2, .	5.0	37
75	Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. Journal of Clinical Investigation, 2017, 127, 2441-2451.	8.2	37
76	Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nature Microbiology, 2019, 4, 800-812.	13.3	36
77	Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. Journal of Clinical Investigation, 2013, 123, 4739-4754.	8.2	36
78	Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood, 2013, 121, 4231-4241.	1.4	34
79	Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1604-1611.	2.0	30
80	Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biology of Blood and Marrow Transplantation, 2020, 26, e101-e112.	2.0	30
81	Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. Journal of Leukocyte Biology, 2012, 91, 667-675.	3.3	29
82	Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host-Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 164-168.	2.0	29
83	A redox cycle with complex II prioritizes sulfide quinone oxidoreductase-dependent H2S oxidation. Journal of Biological Chemistry, 2022, 298, 101435.	3.4	28
84	Immunization with host-type CD8Î±+ dendritic cells reduces experimental acute GVHD in an IL-10â€“dependent manner. Blood, 2010, 115, 724-735.	1.4	26
85	SAG/Rbx2-Dependent Neddylation Regulates T-Cell Responses. American Journal of Pathology, 2016, 186, 2679-2691.	3.8	25
86	Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis. Seminars in Hematology, 2020, 57, 1-6.	3.4	24
87	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	1.2	24
88	Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. Experimental Hematology, 2007, 35, 274-286.	0.4	23
89	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 1492-1497.	2.0	23
90	The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion. Molecular and Cellular Biology, 2020, 40, .	2.3	23

#	Article	IF	Citations
91	Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. Journal of Immunology, 2018, 201, 3443-3455.	0.8	22
92	Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. Nature Immunology, 2021, 22, 1440-1451.	14.5	22
93	Differential susceptibility of C57BL/6NCr and B6.Cg-Ptprca mice to commensal bacteria after whole body irradiation in translational bone marrow transplant studies. Journal of Translational Medicine, 2008, 6, 10.	4.4	20
94	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1426-1434.	2.0	20
95	Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplantation, 2019, 54, 1518-1520.	2.4	18
96	Blocking HDACs boosts regulatory T cells. Nature Medicine, 2007, 13, 1282-1284.	30.7	17
97	A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses. Biology of Blood and Marrow Transplantation, 2007, 13, 1294.e1-1294.e11.	2.0	16
98	IAPs protect host target tissues from graft-versus-host disease in mice. Blood Advances, 2017, 1, 1517-1532.	5.2	15
99	The Role of Dendritic Cells in Graft-Versus-Tumor Effect. Frontiers in Immunology, 2014, 5, 66.	4.8	14
100	The Microbiome and Graft Versus Host Disease. Current Stem Cell Reports, 2015, 1, 39-47.	1.6	14
101	Reprint of: Acute Graft-versus-Host Disease: Novel Biological Insights. Biology of Blood and Marrow Transplantation, 2016, 22, S3-S8.	2.0	13
102	Murine Models of Steroid Refractory Graft-versus-Host Disease. Scientific Reports, 2018, 8, 12475.	3.3	13
103	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biology of Blood and Marrow Transplantation, 2016, 22, 54-60.	2.0	12
104	Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Frontiers in Immunology, 2018, 9, 1110.	4.8	12
105	Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 343-353.	2.0	12
106	LNCing RNA to immunity. Trends in Immunology, 2022, 43, 478-495.	6.8	12
107	SAG/RBX2 E3 Ubiquitin Ligase Differentially Regulates Inflammatory Responses of Myeloid Cell Subsets. Frontiers in Immunology, 2018, 9, 2882.	4.8	11
108	GVHD Prevention: An Ounce Is Better Than a Pound. Biology of Blood and Marrow Transplantation, 2012, 18, S17-S26.	2.0	10

#	Article	IF	Citations
109	Mouse Models in Bone Marrow Transplantation and Adoptive Cellular Therapy. Seminars in Hematology, 2013, 50, 131-144.	3.4	10
110	Regulating Damage from Sterile Inflammation: A Tale of Two Tolerances. Trends in Immunology, 2017, 38, 231-235.	6.8	10
111	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Advances, 2021, 5, 5047-5056.	5.2	10
112	Tolerance without toxicity? Î±1-antitrypsin as a novel alternative to immunosuppression. Expert Review of Clinical Immunology, 2012, 8, 397-399.	3.0	9
113	A Pipeline for Faecal Host DNA Analysis by Absolute Quantification of LINE-1 and Mitochondrial Genomic Elements Using ddPCR. Scientific Reports, 2019, 9, 5599.	3.3	9
114	Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 1747-1753.	2.0	8
115	Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. OncoImmunology, 2015, 4, e1016699.	4.6	8
116	Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. Journal of Innate Immunity, 2017, 9, 126-144.	3.8	8
117	Emerging Therapies in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S125-S131.	2.0	7
118	STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. Biology of Blood and Marrow Transplantation, 2017, 23, 1622-1630.	2.0	7
119	SNARE protein SEC22B regulates early embryonic development. Scientific Reports, 2019, 9, 11434.	3.3	7
120	ATG5-Dependent Autophagy Uncouples T-cell Proliferative and Effector Functions and Separates Graft-versus-Host Disease from Graft-versus-Leukemia. Cancer Research, 2021, 81, 1063-1075.	0.9	7
121	Intracellular sensors of immunity and allogeneic hematopoietic stem cell transplantation. , 2013, , 425-447.		6
122	Host CD8Î±+Dendritic Cells May Be a Key Factor for Separating Graft-versus-Host Disease from Graft-versus-Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 775-776.	2.0	6
123	Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease. Frontiers in Immunology, 2020, 11, 722.	4.8	6
124	ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. Journal of Clinical Investigation, 2021, 131, .	8.2	6
125	RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity. Science Translational Medicine, 2021, 13, .	12.4	6
126	Emerging drugs for acute graft-versus-host disease. Expert Opinion on Emerging Drugs, 2009, 14, 219-232.	2.4	5

#	Article	IF	Citations
127	Editorial: HDAC inhibition begets more MDSCs. Journal of Leukocyte Biology, 2012, 91, 679-681.	3.3	5
128	Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1682-1688.	2.0	5
129	Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice. Blood Advances, 2019, 3, 3977-3981.	5.2	5
130	Deletion of bone marrow myeloperoxidase attenuates chronic kidney disease accelerated atherosclerosis. Journal of Biological Chemistry, 2021, 296, 100120.	3.4	5
131	Benzodiazepine-423, an Inhibitor of Mitochondrial Respiration, Causes Selective Apoptosis of Activated Lymphocytes and Reverses Experimental GVHD While Preserving GVL Effects.. Blood, 2007, 110, 68-68.	1.4	4
132	SEC23A rescues SEC23B-deficient congenital dyserythropoietic anemia type II. Science Advances, 2021, 7, eabj5293.	10.3	4
133	The Difficulty in Diagnosing Cord Colitis. Biology of Blood and Marrow Transplantation, 2014, 20, 906-907.	2.0	3
134	Histone Deacetylase Inhibitors: Novel Immunomodulators. Current Enzyme Inhibition, 2007, 3, 207-215.	0.4	2
135	Editorial: Non-coding RNAs and Graft versus Host Disease. Frontiers in Immunology, 2018, 9, 2713.	4.8	2
136	Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Transactions of the American Clinical and Climatological Association, 2013, 124, 152-62.	0.5	2
137	Donor Tregs suppress the good with the bad after allogeneic BMT. Leukemia Research, 2011, 35, 1541-1542.	0.8	1
138	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. , 2018, , 1650-1668.e10.		1
139	Microbes and Their Metabolites Correlate with Hematopoietic Stem Cell Transplantation Outcomes?. Biology of Blood and Marrow Transplantation, 2018, 24, e7-e8.	2.0	1
140	Pathophysiology of Acute Graft-versus-Host Disease. , 2008, , 563-588.		1
141	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. , 2012, , 303-366.		1
142	Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease. Blood, 2019, 134, 584-584.	1.4	1
143	Allo-Antigen Expression on Both APCS and Tumor Is Required To Elicit an Effective GVL Response after Experimental Allogeneic BMT.. Blood, 2004, 104, 595-595.	1.4	1
144	Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model. Blood, 2015, 126, 229-229.	1.4	1

#	Article	IF	Citations
145	Histone Deacetylase Inhibitors Induce Immuno-Dominant Suppression of Dendritic Cells.. Blood, 2005, 106, 456-456.	1.4	1
146	Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study. Blood, 2019, 134, 3276-3276.	1.4	1
147	Pathobiology of graft-versus-host disease. , 0, , 297-310.		0
148	GVHD: ferocity affects feracitas. Blood, 2017, 129, 1068-1069.	1.4	0
149	Intracellular Sensors and Cellular Metabolism in Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, , 349-374.		0
150	Host Î³d T cells Exacerbate Experimental Acute Graft-Versus-Host Disease through Activation of Host Antigen Presenting Cells.. Blood, 2004, 104, 3045-3045.	1.4	0
151	Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.. Blood, 2007, 110, 39-39.	1.4	0
152	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. Blood, 2015, 126, 647-647.	1.4	0
153	NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT. Blood, 2019, 134, 1926-1926.	1.4	0
154	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. Blood, 2019, 134, 367-367.	1.4	0
155	The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd. Blood, 2021, 138, 2766-2766.	1.4	0
156	Extracorporeal photo-chemotherapy for graft-versus-host disease. Haematologica, 2005, 90, 1013B.	3.5	0